US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

bluebird bio, Inc. - Common Stock (NQ:BLUE)

4.970 UNCHANGED
Last Price Updated: 4:00 PM EDT, May 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 4.970
Bid (Size) 4.000 (1)
Ask (Size) 4.990 (28)
Prev. Close 4.970
Today's Range 4.970 - 4.970
52wk Range 4.970 - 4.970
Shares Outstanding 9,600,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Vertex Pharmaceuticals (VRTX): The Evolution of a Biotech Powerhouse in 2026
As of March 20, 2026, Vertex Pharmaceuticals (NASDAQ: VRTX) has officially transcended its long-held identity as "the cystic fibrosis (CF) company." For over a decade, the Boston-based biotech giant... 
Via Finterra
Topics Intellectual Property
News headline image
The $1.7 Billion Pivot: Agios Pharmaceuticals (AGIO) and the New Frontier of Oral Thalassemia Therapy
On December 23, 2025, the biotechnology landscape shifted for thousands of patients living with chronic anemia. The U.S. Food and Drug Administration (FDA) granted approval to AQVESME (mitapivat),... 
Via PredictStreet
Topics Economy

Performance

More News

Read More
News headline image
Agios Pharmaceuticals Plunges Over 50% as Sickle Cell Drug Delivers Mixed Phase 3 Results
Via MarketMinute
News headline image
Motley Fool Co-Founder David Gardner Reviews Stock Picks ↗
Via The Motley Fool
News headline image
bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital
From bluebird bio
Via Business Wire
News headline image
Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer
From bluebird bio, Inc.
Via Business Wire
News headline image
bluebird bio Reminds Stockholders to Act Now to Tender Shares for Acquisition by Carlyle and SK Capital
From bluebird bio, Inc.
Via Business Wire
News headline image
Carlyle, SK Capital Partners and bluebird bio Provide Updated Tender Instructions
From bluebird bio, Inc.
Via Business Wire
News headline image
Which stocks are moving on Wednesday? ↗
Via Chartmill
News headline image
Top movers analysis in the middle of the day on 2025-05-14: top gainers and losers in today's session. ↗
Via Chartmill
News headline image
Bluebird Bio Shareholders Get New All-Cash Offer From Private Equity ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Via Benzinga
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
Carlyle, SK Capital Partners and bluebird bio Amend Merger Agreement
From bluebird bio, Inc.
Via Business Wire
News headline image
Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital
From bluebird bio, Inc.
Via Business Wire
News headline image
Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio
From bluebird bio, Inc.
Via Business Wire
News headline image
bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement
From bluebird bio, Inc.
Via Business Wire
News headline image
Top stock movements in today's session. ↗
Via Chartmill
News headline image
BlueBird Shares Are Up Today: What's Going On? ↗
Via Benzinga
News headline image
Monday's session: top gainers and losers ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Via Benzinga
News headline image
Gene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock Jumps ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Via Benzinga
News headline image
bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid
From bluebird bio, Inc.
Via Business Wire
News headline image
BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc. - BLUE
From Kahn Swick & Foti, LLC
Via Business Wire

Frequently Asked Questions

Is bluebird bio, Inc. - Common Stock publicly traded?
Yes, bluebird bio, Inc. - Common Stock is publicly traded.
What exchange does bluebird bio, Inc. - Common Stock trade on?
bluebird bio, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for bluebird bio, Inc. - Common Stock?
The ticker symbol for bluebird bio, Inc. - Common Stock is BLUE on the Nasdaq Stock Market
What is the current price of bluebird bio, Inc. - Common Stock?
The current price of bluebird bio, Inc. - Common Stock is 4.970
When was bluebird bio, Inc. - Common Stock last traded?
The last trade of bluebird bio, Inc. - Common Stock was at 05/30/25 04:00 PM ET
What is the market capitalization of bluebird bio, Inc. - Common Stock?
The market capitalization of bluebird bio, Inc. - Common Stock is 47.71M
How many shares of bluebird bio, Inc. - Common Stock are outstanding?
bluebird bio, Inc. - Common Stock has 48M shares outstanding.